A Single Arm Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma After Progression on Standard Systemic Therapy
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 27
- 试验地点
- 2
- 主要终点
- Evaluation of ORR
研究概览
简要总结
The prognosis for unresectable and metastatic biliary tract cancers (BTCs) including cholangiocarcinoma is poor with first line gemcitabine and cisplatin offering a median overall survival of 11.7 months. There is no standard second- or third-line therapy for advanced BTC, and this represents an unmet medical need for novel therapies. The immune system plays a critical role in the development of Advanced Biliary Tract Carcinoma (BTC) and chronic inflammation is a common underlying risk factor for BTC. Vascular endothelial growth factor (VEGF) signaling in BTC may lead to an immune suppression via inadequate tumor antigen presentation and an impaired T cell-mediated immune response directed against tumor antigens. Lenvatinib significantly decreased the population of immunosuppressive tumor-associated macrophages and increased interferon-γ-producing cluster of differentiation 8+ (CD8+) T cells. Addition of programmed cell death protein 1 (PD-1)/programmed death-ligand (PD-L1) inhibitors helps reverse VEGF-mediated immune suppression, restore T cell function, and promote T cell tumor infiltration. The combination of lenvatinib and pembrolizumab has demonstrated promising activity with manageable adverse events in various solid tumor types.
The investigators will assess the efficacy and safety of the combination of pembrolizumab and lenvatinib in patients with advanced BTC who failed standard therapy in this phase II study.
详细描述
Title: A Single Arm Phase II Study of Pembrolizumab in combination with Lenvatinib in Patients with Advanced Biliary Tract Carcinoma after Progression on Standard Systemic Therapy Study Description: The prognosis for unresectable and metastatic biliary tract cancers (BTCs) including cholangiocarcinoma is poor with first line gemcitabine and cisplatin offering a median overall survival of 11.7 months. There is no standard second- or third-line therapy for advanced BTC, and this represents an unmet medical need for novel therapies. The immune system plays a critical role in the development of Advanced Biliary Tract Carcinoma (BTC) and chronic inflammation is a common underlying risk factor for BTC. VEGF signaling in BTC may lead to an immune suppression via inadequate tumor antigen presentation and an impaired T cell-mediated immune response directed against tumor antigens. Lenvatinib significantly decreased the population of immunosuppressive tumor-associated macrophages and increased interferon-γ-producing CD8+ T cells. Addition of PD-1/PD-L1 inhibitors helps reverse VEGF-mediated immune suppression, restore T cell function, and promote T cell tumor infiltration. The combination of lenvatinib and pembrolizumab has demonstrated promising activity with manageable adverse events in various solid tumor types.
The investigators will assess the efficacy and safety of the combination of pembrolizumab and lenvatinib in patients with advanced BTC who failed standard therapy in this phase II study.
Objectives and Endpoints:
Primary Objective: Evaluate the objective response rate (ORR) (RECIST1.1) of lenvatinib in combination with pembrolizumab in patients with advanced BTC after progression on standard systemic therapies Secondary Objective: Evaluate the safety and tolerability of lenvatinib+pembrolizumab in this population; Determine the duration of response (DOR), progression free survival (PFS), and overall survival (OS); Determine the ORR, PFS and OS of subgroups stratified by molecular signatures (tumor mutation burden, PD-L1 expression, microsatellite instability (MSI) status, isocitrate dehydrogenase (IDH) or FGFR mutation/fusion status) in a pre-planned post-hoc analysis; Define molecular correlates of response, including circulating biomarkers and tumor tissue biomarkers Study Population: The study will enroll 40 patients who have unresectable or metastatic, histologically-confirmed advanced BTC. Both male and female patients age of 18 years or older who have failed standard systemic therapy for advanced BTC with measurable disease, adequate bone marrow reserve and hepatic/renal function, and ECOG performance status (PS) 0-1 could be eligible to participate in the study after completing the study enrollment screening tests and procedures.
Phase: II Description of Sites/Facilities Enrolling Participants: The study will be conducted at Jiahui International Cancer Center, Shanghai Jiahui International Hospital, in collaboration with Zhongshan Hospital.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must meet the following criteria in order to be eligible to participate in the study:
- •Unresectable or metastatic, histologically-confirmed advanced BTC (excluding periampullary cancer)
- •Failed standard systemic therapy for advanced BTC due to progression of disease or toxicity
- •Measurable disease
- •Prior chemoembolization, radiofrequency ablation, or radiation to the liver is allowed as long as the patient has measurable disease outside the chemoembolization or radiation area or measurable progression at the site of chemoembolization or radiation
- •ECOG Performance status ≤ 1
- •Life expectancy > 3 months
- •Adequate renal function as defined by Cr ≤ 1.5 upper limit of normal (ULN) or glomerular filtration rate (GFR) ≥ 60 mL/min/1.73 m2
- •Adequate hepatic function as defined by bilirubin ≤ 2.5 x ULN and alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤ 5x ULN
- •Adequate bone marrow reserve as evidenced by ANC > 1500/mcl, Plts >75,000/mcl, Hgb ≥ 9.0g/dl
- •Prothrombin time / Partial thromboplastin time (PT/PTT) <1.5x ULN
- •Urine Protein: Creatinine ratio of <1, if protein is > 2+ on urinalysis
- •Age ≥ 18 years
- •Participants with past or ongoing hepatitis C virus (HCV) infection are eligible for the study. Treated participants must have completed their treatment at least 1 month prior to starting study intervention. Untreated or incompletely treated HCV participants may initiate anti-viral therapy for HCV if liver function remains stable for at least 3 months on study intervention
- •Participants with controlled hepatitis B are eligible for the study, as long as they meet the following criteria:
- •Participants with chronic hepatitis B virus (HBV) infection, defined as HBsAg positive and/or detectable HBV DNA, must be given antiviral therapy for HBV for at least 4 weeks prior to the first dose of study intervention and HBV viral load must be less than 100 IU/ml. prior to the first dose of study treatment. Participants on active HBV therapy with viral loads under 100 IU/ml. should stay on the same therapy throughout study intervention. Antiviral therapy after completion of study intervention should follow local guidelines.
- •Participants with clinically resolved HBV infection, defined as HBsAg negative and anti-hepatitis B core antigen (HBc) positive, and who have an undetectable HBV viral load at screening should be checked every 6 weeks for HBV viral load and treated for HBV if viral load is over 100 IU/ml. Antiviral therapy after completion of study intervention should follow local guidelines.
排除标准
- •Patients who exhibit any of the following conditions at screening will not be eligible to be enrolled to the study:
- •Prior treatment with other VEGF-R directed therapies
- •Periampullary cancer
- •Major surgery or radiation within the 4 weeks prior to enrollment; is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of registration. The treated patients must recover from their relevant treatment(i.e. to≤1 grade or baseline) and from any AEs caused by any previous treatment
- •Uncontrolled hypertension defined by systolic blood pressure (SBP)>150 or diastolic blood pressure (DBP)>90 despite titration of anti-hypertensive medications
- •Active, known or suspected autoimmune disease
- •Congestive heart failure or symptomatic coronary artery disease within 3 months prior to enrollment
- •Cerebrovascular accident within prior 6 months
- •Clinically significant hemorrhage, bleeding event, or thromboembolic disease within six months
- •History of bowel perforation
- •History of (non-infectious) pneumonitis that required steroids or currently has pneumonitis
- •Known history of HIV infection
- •Severely impaired lung function or history of interstitial lung disease
- •Concurrent malignancy (other than adequately treated non-melanoma skin cancer, superficial transitional cell carcinoma of the bladder, and cervical CIS) diagnosed within the past 5 years or any currently active malignancy
- •Positive serum pregnancy test within 72 hours of first dosing of study treatment
- •History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator
研究组 & 干预措施
Interventional Arm
This is an open-label, multi-center, phase II trial of lenvatinib in combination with pembrolizumab in patients with Advanced Biliary Tract Carcinoma (BTC) who have progressed on standard systemic therapy. All participants will be administered Pembrolizumab 200mg IV on day 1 and Lenvatinib 20mg PO daily days 1-21 of each cycle (21 days).
干预措施: Pembrolizumab Injection [Keytruda] (Drug)
Interventional Arm
This is an open-label, multi-center, phase II trial of lenvatinib in combination with pembrolizumab in patients with Advanced Biliary Tract Carcinoma (BTC) who have progressed on standard systemic therapy. All participants will be administered Pembrolizumab 200mg IV on day 1 and Lenvatinib 20mg PO daily days 1-21 of each cycle (21 days).
干预措施: Lenvatinib Mesylate (Drug)
结局指标
主要结局
Evaluation of ORR
时间窗: up to 36 months
Evaluate the objective response rate (ORR) (RECIST1.1) of lenvatinib in combination with pembrolizumab in patients with advanced BTC after progression on standard systemic therapies
次要结局
- Progression-Free Survival (PFS)(up to 36 months)
- Objective Response Rate (ORR) of subgroups burden(up to 36 months)
- All participants who receive at least one dose of study treatment will be evaluable for safety and tolerability through the monitoring of serious and non serious AEs, defined and graded according to NCI CTCAE v5.0.(up to 36 months)
- Duration of Overall Response (DOR)(up to 36 months)
- Overall Survival (OS)(up to 36 months)
- Progression-Free Survival (PFS) of subgroups burden(up to 36 months)
- Overall Survival (OS) of subgroups burden(up to 36 months)